Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab

19Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To report a rare case of central vision loss in a patient with choroideremia. Patients and methods: A retrospective, interventional case report. Results: A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted. Conclusion: Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy.

Cite

CITATION STYLE

APA

Palejwala, N. V., Lauer, A. K., & Weleber, R. G. (2014). Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab. Clinical Ophthalmology, 8, 1675–1679. https://doi.org/10.2147/OPTH.S68243

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free